Bokf, Na Bristol Myers Squibb CO Transaction History

Bokf, Na

$5.52 Billion
Q2 2024

A detailed history of Bokf, Na transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bokf, Na holds 120,062 shares of BMY stock, worth $6.39 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

120,062

Previous 143,343 16.24%

Holding current value

$6.39 Million

Previous $7.77 Million 35.85%

% of portfolio

0.09%

Previous 0.14%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$40.25 - $52.99 $937,060 - $1.23 Million	-23,281 Reduced 16.24%	120,062 $4.99 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $1.29 Million - $1.46 Million	26,816 Added 23.01%	143,343 $7.77 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $568,137 - $677,944	-11,719 Reduced 9.14%	116,527 $5.98 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $1.48 Million - $1.65 Million	-25,483 Reduced 16.58%	128,246 $7.44 Million
Q2 2023 Aug 21, 2023	SELL	$63.71 - $70.74 $1.5 Million - $1.67 Million	-23,599 Reduced 13.31%	153,729 $9.83 Million
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $1.39 Million - $1.58 Million	21,191 Added 13.57%	177,328 $12.3 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $144,835 - $171,505	-2,115 Reduced 1.34%	156,137 $11.2 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $462 - $273,550	-3,560 Reduced 2.2%	158,252 $11.3 Million
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $1.76 Million - $1.94 Million	-24,287 Reduced 13.05%	161,812 $12.5 Million
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $612,955 - $734,988	9,970 Added 5.66%	186,099 $13.6 Million
Q4 2021 Mar 11, 2022	SELL	$53.63 - $62.52 $581,510 - $677,904	-10,843 Reduced 5.8%	176,129 $11 Million
Q3 2021 Nov 10, 2021	SELL	$59.17 - $69.31 $978,375 - $1.15 Million	-16,535 Reduced 8.13%	186,972 $11.1 Million
Q1 2021 Apr 21, 2021	SELL	$59.34 - $66.74 $1.19 Million - $1.34 Million	-20,080 Reduced 8.98%	203,507 $12.8 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $5.98 Million - $6.78 Million	-103,593 Reduced 31.66%	223,587 $13.9 Million
Q3 2020 Oct 30, 2020	BUY	$57.43 - $63.64 $3.26 Million - $3.61 Million	56,709 Added 20.97%	327,180 $19.7 Million
Q2 2020 Aug 12, 2020	BUY	$54.82 - $64.09 $1.8 Million - $2.1 Million	32,758 Added 13.78%	270,471 $15.9 Million
Q1 2020 May 13, 2020	BUY	$46.4 - $67.43 $2.87 Million - $4.17 Million	61,892 Added 35.2%	237,713 $13.3 Million
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $2.24 Million - $2.92 Million	45,462 Added 34.87%	175,821 $11.3 Million
Q3 2019 Nov 13, 2019	BUY	$42.77 - $50.71 $760,578 - $901,775	17,783 Added 15.8%	130,359 $6.61 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $219,976 - $243,246	-4,930 Reduced 4.2%	112,576 $5.11 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $147,316 - $175,657	-3,265 Reduced 2.7%	117,506 $5.61 Million
Q4 2018 Feb 13, 2019	SELL	$48.76 - $63.23 $6.33 Million - $8.21 Million	-129,822 Reduced 51.81%	120,771 $6.28 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $367,179 - $414,149	-6,653 Reduced 2.59%	250,593 $15.6 Million
Q2 2018 Aug 13, 2018	SELL	$50.53 - $62.98 $398,479 - $496,660	-7,886 Reduced 2.97%	257,246 $14.2 Million
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $1.66 Million - $1.91 Million	27,703 Added 11.67%	265,132 $16.8 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $249,590 - $272,117	4,164 Added 1.79%	237,429 $14.6 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $1.5 Million - $1.73 Million	27,078 Added 13.13%	233,265 $14.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	206,187	206,187 $11.5 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.

Account